University Hospitals Case Medical Center chosen by Telesso Technologies as second world class site for clinical trial of peripheral catheter

University Hospitals Case Medical Center has been selected by Telesso Technologies Limited, a global healthcare company, as the second site to enroll patients in a head-to-head trial evaluating its FDA-approved guide wire-assisted peripheral IV catheter versus the industry’s gold standard device for peripheral IV placement.
A peripheral vein is the most common site for insertion of a catheter for short-term diagnostic or therapeutic use. The catheter is placed into the peripheral vein in the arm, below the elbow and is typically passed up inside the vein to a length of 2-3 inches.

Telesso’s uniquely-designed guide wire-assisted peripheral IV catheter device uses a retractable guide wire system that is believed to enable easier IV access, reduce common safety risks, significantly lessen patient pain and discomfort, and provide cost savings to facilities by lowering administrative costs associated with failed IV starts.

End results for the trial could lead to the device being the first clinically meaningful advancement in peripheral IV access since automatic needle retraction catheters and addresses significant unmet needs in peripheral intravenous access. The clinical trial is being conducted at the Surgical Intensive Care Unit (SICU) under Principal Investigator Dr. James Rowbottom, Vice-Chair, Clinical Affairs and CO-Chief SICU; Department of Anesthesiology & Perioperative Medicine, UHCMC.

UHCMC’s Bette Idemoto, PhD, RN, the other Principal Investigator of the trial.

“We are honored to have been selected by the company as a trial site as it affirms our standing in the country,” she said. “This is very exciting for University Hospitals Case Medical Center. The device is so easy to use and intuitive. I can’t wait for it to be in full production so we can use it across the hospital.”

The trial will enroll approximately 400 pediatric, geriatric and oncology patients at three world-class sites who will be treated with either the novel guide-wire assisted peripheral IV catheter or the current standard of care.

“This post-market study represents the advancement of an important innovation in medicine designed to reduce the safety risks and costs traditionally associated with peripheral IV catheter use, and improve patient care,” said Telesso’s CEO Nelson Stacks. “We are very excited to add University Hospitals Case Medical Center to our trial as it is a world renowned medical facility.”

About University Hospitals

With 150 locations throughout Northeast Ohio, University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians. At the core of our health system is University Hospitals Case Medical Center. The primary affiliate of Case Western Reserve University School of Medicine, University Hospitals Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Ireland Cancer Center, a part of the NCI-designated Case Comprehensive Cancer Center, which holds the nation's highest designation by the National Cancer Institute of Comprehensive Cancer Center. For more information, go to www.uhhospitals.org.

For more information, visit Telesso’s web site at http://www.telesso.com

CONTACT: Nelson K. Stacks, CEO, e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it , or Ian Atkin, Chief Financial Officer, Australia +61 2 9805 0022, both of Telesso Technologies

Press Release published by Get the Word Out